Targeted Drug Delivery in Autoimmune Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (20 March 2024) | Viewed by 200
Special Issue Editors
Interests: autoimmunity; targeted therapy; natural products
Special Issues, Collections and Topics in MDPI journals
Interests: homing peptides; peptide phage display; molecular biology; cancer biology; nanobiomedicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, are chronic conditions affecting people worldwide. Several potent drugs are available for the treatment of these diseases; however, their prolonged use is associated with severe adverse reactions. This is partly because while these drugs are intended to target the diseased site (e.g., the joints or the brain), they are still distributed systemically after oral intake or injection. Furthermore, many of these drugs have limitations of reduced efficacy as well as poor solubility and bioavailability. Therefore, better drug delivery modalities are needed to overcome these significant limitations. Advancements in nanotechnology and the identification of tissue-homing/cell-specific ligands are paving the way for targeted drug delivery for various tumors. Thus, there is now an impetus to develop and apply similar approaches for the treatment of autoimmune diseases.
Authors are cordially invited to submit their original research papers, reviews, and communications, addressing the aforementioned areas, to this Special Issue, ‘Targeted Drug Delivery in Autoimmune Diseases’.
Prof. Dr. Kamal Moudgil
Prof. Dr. Tambet Teesalu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- autoimmune diseases
- nanoparticles
- tissue-homing ligands/peptides
- tissue-penetrating peptides
- endothelial cell transport
- blood–tissue barriers
- targeted therapy
- targeted drug delivery
- theranostics
